U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with P

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
182854 Q3 2022 PEG-32 HYDROGENATED PALM GLYCERIDES ORAL CAPSULE, EXTENDED RELEASE 8mg Correction
182856 Q3 2022 PETROLATUM OPHTHALMIC OINTMENT 97.00 %w/w Correction
182857 Q4 2022 PETROLATUM OPHTHALMIC OINTMENT 88.40 %w/w Correction
182858 Q3 2022 PHENOXYETHANOL TOPICAL GEL 14mg Correction
182859 Q4 2022 PHENOXYETHANOL TOPICAL GEL 0.70 %w/w Correction
182860 Q3 2022 POLOXAMER 124 TOPICAL GEL 6mg Correction
182861 Q4 2022 POLOXAMER 124 TOPICAL GEL 4mg Correction
182862 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) ENDOSINUSIAL IMPLANT 1.35 mg Correction
182864 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) INTRAVITREAL IMPLANT 116.00 mg Correction
182866 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) INTRAVITREAL INJECTION 116.00 mg Correction
182868 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) SUBCUTANEOUS INJECTION, SOLUTION 533.00 mg Correction
182870 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) SUBCUTANEOUS INJECTION, SUSPENSION, EXTENDED RELEASE 48mg Correction
182872 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 63000 MW) INTRAMUSCULAR INJECTION 60.70 mg Correction
182874 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 63000 MW) SUBCUTANEOUS IMPLANT 16.20 mg Correction
182876 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (75:25; 20000 MW) INTRAMUSCULAR INJECTION 145mg Correction
182878 Q3 2022 POLYSORBATE 80 RECTAL SOLUTION 840mg Correction
182879 Q4 2022 POLYSORBATE 80 RECTAL SOLUTION 315mg Correction
182880 Q3 2022 POLYVINYL ALCOHOL ORAL TABLET, ORALLY DISINTEGRATING 10mg Correction
182881 Q4 2022 POLYVINYL ALCOHOL ORAL TABLET, ORALLY DISINTEGRATING 6mg Correction
182882 Q3 2022 PROPYLENE GLYCOL ORAL POWDER 330mg Correction
182883 Q4 2022 PROPYLENE GLYCOL ORAL POWDER 55.00 mg Correction
182974 Q4 2022 POLOXAMER 188 ORAL LIQUID, EXTENDED RELEASE 0.50 mg/ 1.00 ml 6mg Deletion
182975 Q4 2022 POLYESTER RAYON TRANSDERMAL SYSTEM 96.50 mg Deletion
182976 Q4 2022 POLYETHYLENE GLYCOL 6000 VAGINAL TABLET, FILM COATED 0.06 mg Deletion
182977 Q4 2022 POLYOXYL 20 CETOSTEARYL ETHER TOPICAL CREAM, AUGMENTED 3.00 %w/w Deletion
182978 Q4 2022 POLYVINYL ALCOHOL (108000 MW) ORAL TABLET 38.27 mg Deletion
182979 Q4 2022 POLYVINYL ALCOHOL (108000 MW) ORAL TABLET, EXTENDED RELEASE 11.58 mg 116mg Deletion
182980 Q4 2022 POVIDONE K30 BUCCAL TABLET, EXTENDED RELEASE 0.50 mg 1mg Deletion
182981 Q4 2022 POVIDONE K30 ORAL LIQUID, EXTENDED RELEASE 1.03 mg/ 1.00 ml 12mg Deletion
182982 Q4 2022 PROPYLENE GLYCOL ORAL TABLET, COATED PARTICLES 4.20 mg 34mg Deletion
183105 Q3 2022 PEG-32 HYDROGENATED PALM GLYCERIDES ORAL CAPSULE 12.60 mg MDE Replacement
183107 Q3 2022 POLOXAMER 407 TOPICAL GEL 0.20 %w/w MDE Replacement
183108 Q4 2022 POLOXAMER 407 TOPICAL GEL 13mg MDE Replacement
183109 Q3 2022 POLY(DL-LACTIC-CO-GLYCOLIC ACID), (75:25; 20000 MW) INTRAMUSCULAR INJECTION, POWDER, FOR SUSPENSION 3.31 %w/v MDE Replacement
183111 Q3 2022 POLYSORBATE 40 TOPICAL GEL 0.20 %w/w MDE Replacement
183112 Q4 2022 POLYSORBATE 40 TOPICAL GEL 13mg MDE Replacement
183113 Q3 2022 POVIDONE ORAL CAPSULE, EXTENDED RELEASE 72.00 mg MDE Replacement
183114 Q4 2022 POVIDONE ORAL CAPSULE, EXTENDED RELEASE 120mg MDE Replacement
183115 Q3 2022 POVIDONE K25 ORAL TABLET, FILM COATED, EXTENDED RELEASE 10.70 mg MDE Replacement
183116 Q4 2022 POVIDONE K25 ORAL TABLET, FILM COATED, EXTENDED RELEASE 11mg MDE Replacement
183117 Q3 2022 POVIDONE K30 ORAL SOLUTION 30.50 mg/ 1.00 ml MDE Replacement
183118 Q4 2022 POVIDONE K30 ORAL SOLUTION 90mg MDE Replacement
183119 Q3 2022 POVIDONE K30 VAGINAL INSERT 49.00 mg MDE Replacement
183120 Q4 2022 POVIDONE K30 VAGINAL INSERT 147mg MDE Replacement
183121 Q3 2022 POWDERED CELLULOSE ORAL POWDER, FOR SUSPENSION NA MDE Replacement
183122 Q4 2022 POWDERED CELLULOSE ORAL POWDER, FOR SUSPENSION 1455mg MDE Replacement
183123 Q3 2022 PROPYLENE GLYCOL ORAL CAPSULE, LIQUID FILLED 17.70 mg MDE Replacement
183124 Q4 2022 PROPYLENE GLYCOL ORAL CAPSULE, LIQUID FILLED 42mg MDE Replacement
183125 Q3 2022 PROPYLPARABEN SODIUM ORAL POWDER, FOR SUSPENSION 1.23 mg/ 5.00 ml MDE Replacement
183126 Q4 2022 PROPYLPARABEN SODIUM ORAL POWDER, FOR SUSPENSION 16mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: October 1, 2022
Database Last Updated: October 19, 2022

Back to Top